Exploratory Study of Efficacy on Selected Natural Extracts Reducing Post Prandial Blood Glucose Response

February 4, 2020 updated by: Unilever R&D

An Exploratory Study of Efficacy and Tolerance on Selected Natural Extracts, With the Potential of Reducing Post Prandial Blood Glucose Response, in Healthy Indian Adult Subjects

Randomized, balanced, incomplete block design exploratory study of efficacy, with 8 active treatments (4 treatments per subject; 35 or 37 subjects per treatment) compared to a reference treatment (all 72 subjects).

Study Overview

Detailed Description

Incomplete block design cross over study in which the subjects consumed commercial rice porridge (60 grams of extruded rice to which 300 ml of boiling water was added) in the morning in a fasted state. On each visit one of the seven different natural exacts was mixed into this porridge just before consumption. The reference was consumed by all subjects and consisted of plain porridge with no extract added.

Study Type

Interventional

Enrollment (Actual)

72

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Gujarat
      • Ahmedabad, Gujarat, India, 382481
        • Lambda Therapeutics Research Ttd

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 50 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Is the volunteer willing to give his consent to participate in the study in writing?
  2. Is the volunteer between the age of >20 and <50 yrs?
  3. Is the volunteer's Body Mass Index (BMI) in between >18 and <25 kg/m2?
  4. Lactase deficient as indicated by screening test1
  5. Is the volunteer apparently healthy? [No medical conditions which might affect study measurement, as judged by study physician or measured by questionnaire, and/or assessed by haematology, blood chemistry and urinalysis]
  6. Is the volunteer willing to comply to study protocol during the study?
  7. Is the volunteer agreeing to be informed about medically relevant personal test-results by study physician?
  8. Is the volunteer willing to refrain from drinking of alcohol on and one day before the blood withdrawal?
  9. Is the fasting blood glucose value of the volunteer is >3.4 and <6.1 mmol/ litre (i.e. 62-110 mg/dl)?
  10. Is the Haemoglobin level within normal reference range as judged by the research physician?
  11. Is the volunteer literate?

Exclusion Criteria:

  1. Is the volunteer an employee of Unilever, Hindustan Lever, or Lambda Therapeutics Research?
  2. Has the volunteer participated in any other biomedical study 3 months before screening visit day of this study and/or participating in any other biomedical study during the study period?
  3. Does the volunteer take too much of alcohol (> 120 ml / week)?
  4. Is the volunteer on a medically prescribed/slimming diet?
  5. Does the volunteer work in night shifts (between 23.00 and 6.00 hrs) in the week preceding or during the study?
  6. Is the volunteer using any medication including traditional medicines, vitamins, tonics which might interfere with study measurements, as judged by the PI and/or study physician?
  7. Does the volunteer engage in intense exercise > 10h/week? (Intense exercise is defined as exercise which induces sweating and causes sufficient breathlessness to limit conversation)
  8. Has the volunteer reported weight loss/gain > 10% of body weight in the 6 months preceding screening?
  9. Has the volunteer donated any blood for 2 months prior to screening visit?
  10. Does the volunteer urine analysis show any drug abuse?
  11. Is the volunteer allergic to any food or cosmetics?
  12. Does the volunteer smoke or consume tobacco in any form, and/or was smoking or consuming tobacco in any form for 6 months preceding the study and/or will be smoking or consuming tobacco in any form, during the study?
  13. If female, is the volunteer pregnant or will she be planning pregnancy during the study period?
  14. If female, is the volunteer lactating or has been lactating for 6 weeks before pre-study investigation and/or during the study period?

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Mulberry fruit extract
1.5 g of mulberry fruit powdered extract mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
Experimental: Mulberry leaf extract
1.0 g of mulberry leaf powdered extract mixed into aa bowl containing 60 g of extruded rice + 300 ml of boiling water
Experimental: White bean extract
3 g of white bean powdered extract mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
Experimental: Apple extract
2 g of apple powdered extract standardized in phloridzin mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
Experimental: Elderberry extract
2 g of elderberry powder extract mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
Experimental: Turmeric extract
0.18 g of curcumin powdered extract mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
Experimental: Turmeric extract + Apple extract
0.18 g of curcumin powdered extract + 2 g of apple powdered extract standardized in phloridzin mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
Experimental: Turmeric extract + Elderberry extract
0.18 g of curcumin powdered extract + 2 g of elderberry powder extract mixed into aa bowl containing 60 g of extruded rice + 300 ml of boiling water
Placebo Comparator: Rice porridge control
Bowl containing 60 g of extruded rice + 300 ml of boiling water

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Post-prandial blood glucose
Time Frame: Positive incremental Area under the glucose versus time Curve between 0 (before) and 2 hours.
Glucose concentration in venous plasma
Positive incremental Area under the glucose versus time Curve between 0 (before) and 2 hours.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Breath hydrogen excretion
Time Frame: Fifteen minutes before (basal) and 65, 125, 185, 245, 305, 365 and 425 minutes after the ingestion of the test products
Hydrogen gas in exhaled breath. When a subject produced 10 ppm hydrogen or more above the basal breath hydrogen level the treatment was regarded as a "positive"
Fifteen minutes before (basal) and 65, 125, 185, 245, 305, 365 and 425 minutes after the ingestion of the test products
Intestinal discomfort
Time Frame: Ten minutes before (baseline) and at 130, 250, 370 and 420 minutes after the ingestion of the test products.
An intestinal discomfort questionnaire was administered. The questionnaire asked whether subjects had experienced 1) flatulence, 2) nausea, 3) bloating or 4) pain in the bowels. Percentage of "Yes" scores was calculated per discomfort.
Ten minutes before (baseline) and at 130, 250, 370 and 420 minutes after the ingestion of the test products.
Stool consistency and number of stools
Time Frame: 24 hours before study product intake, during 7 hour the test day and in the 17 hours after the test day (telephone interview).
Stool consistency was evaluated by semi-quantitative Bristol scale (score between 1 = constipation and 7 = watery diarrhea).
24 hours before study product intake, during 7 hour the test day and in the 17 hours after the test day (telephone interview).

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Post-prandial serum insulin
Time Frame: Total Area under the insulin versus time Curve 0-2 hours after the intake.
Post-prandial serum insulin Area under versus time curves
Total Area under the insulin versus time Curve 0-2 hours after the intake.
Glucose in urine
Time Frame: Subjects were asked to empty their bladder before study product intake (-20 minutes) and again before leaving the site ( 450 minutes). In these two samples and in all additional urine samples voided while subjects were on site, glucose was analyzed
Glucose in urine was measured using dipsticks with a detection limit of 2.28 mmol/L
Subjects were asked to empty their bladder before study product intake (-20 minutes) and again before leaving the site ( 450 minutes). In these two samples and in all additional urine samples voided while subjects were on site, glucose was analyzed

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: David Mela, Dr., Unilever R&D Vlaardingen (retired)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 24, 2011

Primary Completion (Actual)

January 6, 2012

Study Completion (Actual)

January 6, 2012

Study Registration Dates

First Submitted

January 31, 2020

First Submitted That Met QC Criteria

February 4, 2020

First Posted (Actual)

February 6, 2020

Study Record Updates

Last Update Posted (Actual)

February 6, 2020

Last Update Submitted That Met QC Criteria

February 4, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • FDS-NAA-0334

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Blood Glucose

Clinical Trials on Mulberry fruit

Subscribe